CN114805350B - Benzo heterocycle-pyridone derivative, and preparation method and application thereof - Google Patents
Benzo heterocycle-pyridone derivative, and preparation method and application thereof Download PDFInfo
- Publication number
- CN114805350B CN114805350B CN202210609107.0A CN202210609107A CN114805350B CN 114805350 B CN114805350 B CN 114805350B CN 202210609107 A CN202210609107 A CN 202210609107A CN 114805350 B CN114805350 B CN 114805350B
- Authority
- CN
- China
- Prior art keywords
- compound
- ezh2
- cancer
- brd4
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 44
- 125000005605 benzo group Chemical group 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 83
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims abstract description 36
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims abstract description 35
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 27
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract description 27
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract description 27
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract description 27
- 108091005625 BRD4 Proteins 0.000 claims abstract description 26
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 claims abstract description 26
- 230000000694 effects Effects 0.000 claims abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
- 201000010099 disease Diseases 0.000 claims abstract description 14
- 239000003112 inhibitor Substances 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 10
- 206010061218 Inflammation Diseases 0.000 claims abstract description 7
- 230000004054 inflammatory process Effects 0.000 claims abstract description 7
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 6
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims abstract description 6
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims abstract description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 6
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 6
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims abstract description 6
- 201000003444 follicular lymphoma Diseases 0.000 claims abstract description 6
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 6
- 201000005202 lung cancer Diseases 0.000 claims abstract description 6
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 6
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 6
- 206010061598 Immunodeficiency Diseases 0.000 claims abstract description 5
- 208000029462 Immunodeficiency disease Diseases 0.000 claims abstract description 5
- 208000015114 central nervous system disease Diseases 0.000 claims abstract description 5
- 230000007813 immunodeficiency Effects 0.000 claims abstract description 5
- 230000009385 viral infection Effects 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- -1 p-toluenesulfonyl Chemical group 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- 230000001394 metastastic effect Effects 0.000 claims description 8
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 8
- 238000011065 in-situ storage Methods 0.000 claims description 7
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- DQXKOHDUMJLXKH-PHEQNACWSA-N (e)-n-[2-[2-[[(e)-oct-2-enoyl]amino]ethyldisulfanyl]ethyl]oct-2-enamide Chemical compound CCCCC\C=C\C(=O)NCCSSCCNC(=O)\C=C\CCCCC DQXKOHDUMJLXKH-PHEQNACWSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 54
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 11
- 125000000623 heterocyclic group Chemical group 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 239000002994 raw material Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- OUQVKRKGTAUJQA-UHFFFAOYSA-N n-[(1-chloro-4-hydroxyisoquinolin-3-yl)carbonyl]glycine Chemical compound C1=CC=CC2=C(O)C(C(=O)NCC(=O)O)=NC(Cl)=C21 OUQVKRKGTAUJQA-UHFFFAOYSA-N 0.000 description 6
- FKSFKBQGSFSOSM-QFIPXVFZSA-N 1-[(2S)-butan-2-yl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-methyl-6-[6-(1-piperazinyl)-3-pyridinyl]-4-indolecarboxamide Chemical compound C1=C2N([C@@H](C)CC)C=C(C)C2=C(C(=O)NCC=2C(NC(C)=CC=2C)=O)C=C1C(C=N1)=CC=C1N1CCNCC1 FKSFKBQGSFSOSM-QFIPXVFZSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- UUWSLBWDFJMSFP-UHFFFAOYSA-N bromomethylcyclohexane Chemical compound BrCC1CCCCC1 UUWSLBWDFJMSFP-UHFFFAOYSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- LGAJYTCRJPCZRJ-UHFFFAOYSA-N 2-bromopentane Chemical compound CCCC(C)Br LGAJYTCRJPCZRJ-UHFFFAOYSA-N 0.000 description 3
- IMQJERUFPGBLTJ-UHFFFAOYSA-N 4-(aminomethyl)-1-methyl-5,6,7,8-tetrahydro-2H-isoquinolin-3-one Chemical compound NCC=1C(NC(=C2CCCCC12)C)=O IMQJERUFPGBLTJ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- YYONCBWTWPVWRT-UHFFFAOYSA-N 6-bromo-1h-indazole-4-carboxylic acid Chemical compound OC(=O)C1=CC(Br)=CC2=C1C=NN2 YYONCBWTWPVWRT-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 102000001805 Bromodomains Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- OZQXZSIVKVCSDF-UHFFFAOYSA-N ethyl 3-methyl-1h-indole-2-carboxylate Chemical compound C1=CC=C2C(C)=C(C(=O)OCC)NC2=C1 OZQXZSIVKVCSDF-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 150000002367 halogens Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- JRSMPKFKNDUBAK-UHFFFAOYSA-N methyl 6-bromo-1-butan-2-ylindole-4-carboxylate Chemical compound C1=C(Br)C=C2N(C(C)CC)C=CC2=C1C(=O)OC JRSMPKFKNDUBAK-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- PCJPGNCABBDNJU-UHFFFAOYSA-N 3-(aminomethyl)-4,6-dimethyl-1h-pyridin-2-one Chemical compound CC1=CC(C)=C(CN)C(=O)N1 PCJPGNCABBDNJU-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- VTOQFOCYBTVOJZ-UHFFFAOYSA-N 3-bromopentane Chemical compound CCC(Br)CC VTOQFOCYBTVOJZ-UHFFFAOYSA-N 0.000 description 1
- ICGLPKIVTVWCFT-UHFFFAOYSA-N 4-methylbenzenesulfonohydrazide Chemical compound CC1=CC=C(S(=O)(=O)NN)C=C1 ICGLPKIVTVWCFT-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- CHASPSXISNLSOM-UHFFFAOYSA-N 6-bromo-1-butan-2-yl-3-methylindole-4-carboxylic acid Chemical compound C1=C(Br)C=C2N(C(C)CC)C=C(C)C2=C1C(O)=O CHASPSXISNLSOM-UHFFFAOYSA-N 0.000 description 1
- CWZRACDIDASDPP-UHFFFAOYSA-N 6-bromo-1-butan-2-yl-n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-methylindole-4-carboxamide Chemical compound C1=C(Br)C=C2N(C(C)CC)C=C(C)C2=C1C(=O)NCC1=C(C)C=C(C)NC1=O CWZRACDIDASDPP-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108091005575 Bromodomain-containing proteins Proteins 0.000 description 1
- 108050009021 Bromodomains Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108700041730 Drosophila z Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010036115 Histone Methyltransferases Proteins 0.000 description 1
- 102000011787 Histone Methyltransferases Human genes 0.000 description 1
- 101000601724 Homo sapiens Paired box protein Pax-5 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100037504 Paired box protein Pax-5 Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 101100273253 Rhizopus niveus RNAP gene Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000005441 aurora Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229940125763 bromodomain inhibitor Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- HOOGOXBFMBFNHN-UHFFFAOYSA-N cyclopentane;hydrobromide Chemical compound Br.C1CCCC1 HOOGOXBFMBFNHN-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- AULOCTQDDGBISJ-UHFFFAOYSA-N methyl 6-bromo-1-butan-2-yl-3-methylindole-4-carboxylate Chemical compound C1=C(Br)C=C2N(C(C)CC)C=C(C)C2=C1C(=O)OC AULOCTQDDGBISJ-UHFFFAOYSA-N 0.000 description 1
- KPFSQBKJYHWFME-UHFFFAOYSA-N methyl 6-bromo-1h-indole-4-carboxylate Chemical compound COC(=O)C1=CC(Br)=CC2=C1C=CN2 KPFSQBKJYHWFME-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a benzo heterocycle-pyridone derivativeAnd a preparation method and application thereof, belonging to the pharmaceutical field. The structure of the benzoheterocycle-pyridone derivative is shown as a formula I. Experimental results show that the compound can effectively inhibit the activity of EZH2 or BRD4, and particularly the compounds 1-3 and 5 can simultaneously effectively inhibit the activity of EZH2 and BRD 4. Therefore, the compound can be used for preparing EZH2 and/or BRD4 inhibitors, and medicines for preventing and/or treating diseases related to EZH2 and/or BRD4 activity (including but not limited to follicular lymphoma, diffuse large B cell lymphoma, breast cancer, lung cancer, colorectal cancer, prostatic cancer, gastric cancer, inflammation, pancreatic cancer, cardiovascular diseases, central nervous system diseases and immunodeficiency virus infection), and has wide application prospect.
Description
Technical Field
The invention belongs to the field of pharmacy, and particularly relates to a benzo heterocycle-pyridone derivative, a preparation method and application thereof.
Background
Malignant tumors are one of the diseases with highest mortality in the world, and the development mechanism thereof is always one of hot spots of biomedical research. Drosophila zeste gene enhancer homolog 2 (enhancer of zeste homolog, EZH 2) is a histone methyltransferase that regulates normal physiological functions of cells by catalyzing methylation of histone H3 lysine 27 (H3K 27) to control expression of various genes. Various human diseases (e.g., cancer, inflammation, etc.) are associated with EZH2 imbalance, and EZH2 overexpression can lead to the development and progression of cancer. Dysregulation of EZH2 exists in a variety of cancers, such as follicular lymphoma and diffuse large B-cell lymphoma, and is associated with clinically poor prognosis and efficacy. In addition, EZH2 disorders are also common in solid tumors such as breast cancer, lung cancer, colorectal cancer, prostate cancer, and gastric cancer.
GSK126 is a representative EZH2 inhibitor, and has obvious regulation effect on the over expression of EZH2 genes. Research has reported that GSK126 has better prevention and treatment effects on non-solid tumors. However, GSK126 is not ideal for solid tumors, greatly limiting its clinical studies and applications. It was found that the EZH2 inhibitor induces activated H3K27 acetylation (H3K 27 ac) which is an important cause of solid tumor resistance to EZH2 inhibitors.
Bromodomain protein 4 (bromodomain-containing protein, brd 4), another important highly proprietary target in the epigenetic family, recognizes and binds to acetylated lysine residues on histones (acetylated lysine residues, KAc) as a transcription cofactor, recruits proteins to the vicinity of promoters and enhancers, and regulates transcription processes by coupling to RNA polymerase II (RNAP II), promoting aberrant expression of oncogenes such as c-Myc, NF- κb, aurora B, PAX5, and BCL-XL, and regulating expression of downstream effector proteins involved in disease development. Various human diseases, such as cancer, inflammation, cardiovascular diseases, central Nervous System (CNS) diseases and Human Immunodeficiency Virus (HIV) infections, etc., are associated with BRD4 disorders, and it has been found that BRD4 inhibitors have better control effects on a variety of solid tumors including pancreatic cancer.
In order to improve the therapeutic effect of the medicine and expand the applicable indication range of the medicine, the development of the EZH2/BRD4 double-target inhibitor has important significance.
Disclosure of Invention
The invention aims to provide a benzo heterocycle-pyridone derivative, a preparation method and application thereof.
The invention specifically provides a compound shown as a formula I, or pharmaceutically acceptable salts, stereoisomers, solvates and deuterated compounds thereof:
x is selected from C 1-6 Alkyl, 3-6 membered saturated cycloalkyl, 3-6 membered saturated heterocyclyl, LZ; l is selected from 1-3 methylene groups, Z is selected from 3-6 membered saturated cycloalkyl and 3-6 membered saturated heterocyclic group;
y is selected from hydrogen, C 1-6 An alkyl group;
w is selected from CH or N;
R 1 selected from hydrogen, C 1-6 Alkyl, R 2 Selected from hydrogen, C 1-6 An alkyl group; or R is 1 And R is R 2 Connected into a ring;
R 3 selected from hydrogen, C 1-6 An alkyl group;
R 4 selected from hydrogen, C 1-6 An alkyl group.
Further, the structure of the compound is shown as a formula II:
wherein X is selected from C 1-5 Alkyl, 3-6 membered saturated cycloalkyl, 3-6 membered saturated heterocyclyl, LZ; l is selected from 1-2 methylene groups, Z is selected from 3-6 membered saturated cycloalkyl and 3-6 membered saturated heterocyclic group;
y is selected from hydrogen, C 1-3 An alkyl group;
w is selected from CH or N.
Further, the structure of the compound is shown in a formula III:
wherein X is selected from C 1-5 Alkyl, 5-6 membered saturated cycloalkyl, 5-6 membered saturated heterocyclyl, LZ; l is selected from 1-2 methylene groups, Z is selected from 5-6 membered saturated cycloalkyl and 5-6 membered saturated heterocyclic group.
Further, the structure of the compound is shown as a formula IV:
wherein X is selected from C 1-5 Alkyl, 3-6 membered saturated cycloalkyl, 3-6 membered saturated heterocyclyl, LZ; l is selected from 1-2 methylene groups, Z is selected from 3-6 membered saturated cycloalkyl and 3-6 membered saturated heterocyclic group;
y is selected from hydrogen, C 1-3 An alkyl group;
w is selected from CH or N.
Further, the structure of the compound is shown as a formula V:
wherein X is selected from C 1-5 Alkyl, 5-6 membered saturated cycloalkyl, 5-6 membered saturated heterocyclyl, LZ; l is selected from 1-2 methylene groups, Z is selected from 5-6 membered saturated cycloalkyl and 5-6 membered saturated heterocyclic group.
Further, the compound is selected from:
the invention also provides a method for preparing the compound, which comprises the following steps:
(1) Carrying out hydrolysis reaction on the compound I-1 to obtain a compound I-2;
(2) Reacting the compound I-2 with a compound I-3 to obtain I-4;
(3) Reacting the compound I-4 with a compound I-5, and then deprotecting to obtain a compound shown in the formula I;
therein, X, Y, W, R 1 -R 4 As described above; t is halogen, preferably bromine; r is R 5 The amino protecting group is preferably p-toluenesulfonyl.
The invention also provides a medicine for preventing and/or treating diseases related to EZH2 and/or BRD4 activity, which is a preparation prepared by taking the compound or pharmaceutically acceptable salts, stereoisomers, solvates and deuterated compounds thereof as active ingredients and adding pharmaceutically acceptable auxiliary materials.
The invention also provides application of the compound or pharmaceutically acceptable salts, stereoisomers, solvates and deuterated compounds thereof in preparing the EZH2 and/or BRD4 inhibitor.
Further, the EZH2 and/or BRD4 inhibitor is a medicament for preventing and/or treating diseases related to EZH2 and/or BRD4 activity; preferably, the disease associated with EZH2 and/or BRD4 activity is follicular lymphoma, diffuse large B-cell lymphoma, breast cancer, lung cancer, colorectal cancer, prostate cancer, gastric cancer, inflammation, pancreatic cancer, cardiovascular disease, central nervous system disease, immunodeficiency virus infection;
more preferably, the pancreatic cancer is metastatic pancreatic cancer or orthotopic pancreatic cancer.
Definition of terms used in connection with the present invention: unless otherwise indicated, the initial definitions provided for terms herein apply to the terms throughout the specification; for terms not specifically defined herein, the meanings that one skilled in the art can impart based on the disclosure and the context.
The minimum and maximum values of the carbon atom content of the hydrocarbon groups are indicated by a prefix, e.g. prefix C a~b Alkyl means any alkyl group containing from "a" to "b" carbon atoms. For example, C 1-6 Alkyl refers to straight or branched chain alkyl groups containing 1 to 6 carbon atoms.
Halogen is fluorine, chlorine, bromine or iodine.
"deuterated compound" refers to a compound obtained by substituting one or more hydrogen atoms in the compound with deuterium.
By "pharmaceutically acceptable" is meant that the carrier, vehicle, diluent, adjuvant, and/or salt formed is generally chemically or physically compatible with the other ingredients comprising the pharmaceutical dosage form, and physiologically compatible with the recipient.
"salts" are acidic and/or basic salts formed with inorganic and/or organic acids and/or bases of a compound or stereoisomer thereof, and also include zwitterionic salts (inner salts) and also include quaternary ammonium salts, for example alkylammonium salts. These salts may be obtained directly in the final isolation and purification of the compounds. Or by mixing the compound, or a stereoisomer thereof, with a suitable amount (e.g., equivalent) of an acid or base. These salts may be obtained by precipitation in solution and collected by filtration, or recovered after evaporation of the solvent, or by lyophilization after reaction in an aqueous medium.
The pharmaceutically acceptable salt of the present invention may be the hydrochloride, sulfate, citrate, benzenesulfonate, hydrobromide, hydrofluoric acid, phosphate, acetate, propionate, succinate, oxalate, malate, succinate, fumarate, maleate, tartrate or trifluoroacetate salt of the compound.
Experimental results show that the compound can effectively inhibit the activity of EZH2 or BRD4, and particularly the compounds 1-3 and 5 can simultaneously effectively inhibit the activity of EZH2 and BRD 4. Thus, the compounds of the present invention may be used in the preparation of EZH2 and/or BRD4 inhibitors, and in the prevention and/or treatment of diseases associated with EZH2 and/or BRD4 activity, including but not limited to follicular lymphoma, diffuse large B-cell lymphoma, breast cancer, lung cancer, colorectal cancer, prostate cancer, gastric cancer, inflammation, pancreatic cancer, cardiovascular disease, central nervous system disease, immunodeficiency virus infection.
Proliferation inhibition activity experiments on tumor cell lines further prove that the compound can effectively inhibit the activity of AsPC-1 (human metastatic pancreatic cancer cells) and BxPC-3 (human in-situ pancreatic cancer cells). Thus, the compounds of the present invention can be used for the preparation of a medicament for the prevention and/or treatment of pancreatic cancer (including metastatic pancreatic cancer or pancreatic cancer in situ).
The preparation method of the compound is simple, the raw materials are easy to obtain, the compound is suitable for industrial production, and the application prospect is wide.
It should be apparent that, in light of the foregoing, various modifications, substitutions and alterations can be made herein without departing from the spirit and scope of the invention as defined by the appended claims.
The above-described aspects of the present invention will be described in further detail below with reference to specific embodiments in the form of examples. It should not be understood that the scope of the above subject matter of the present invention is limited to the following examples only. All techniques implemented based on the above description of the invention are within the scope of the invention.
Detailed Description
The raw materials and equipment used in the invention are all known products and are obtained by purchasing commercial products.
The invention is further illustrated below with reference to examples. The examples are intended to be illustrative of the invention only and are not intended to be limiting in any way.
Example 1: preparation of 1- (sec-butyl) -N- ((4, 6-dimethyl-2-oxo-1, 2-dihydropyridin-3-yl) methyl) -6- (6-methyl-7-oxo-6, 7-dihydro-1H-pyrrolo [2,3-C ] pyridin-4-yl) -1H-indole-4-carboxamide (Compound 1)
Step 1 preparation of intermediate methyl-6-bromo-1-sec-butyl-1H-indole-4-carboxylic acid methyl ester
Sodium hydride (5.66 g,141.7 mmol) was placed in DMF (100 ml) of methyl 6-bromo-4-indolecarboxylate (30 g,118.1 mmol), stirred in ice for 20 min, 2-bromopentane (29.1 g,22.5 mmol) was added while maintaining the ice, the ice was removed, and the reaction was allowed to warm to room temperature overnight by TLC. The reaction solution was diluted with water, extracted with ethyl acetate, and the organic phases were combined, washed with water and saturated brine, and dried over anhydrous sodium sulfate, and concentrated in vacuo to give the product in 40% yield.
Step 2. Preparation of intermediate 6-bromo-1H-indole-4-carboxylic acid
methyl-6-bromo-1-sec-butyl-1H-indole-4-carboxylate (2.54 g,10 mmol) as an intermediate was dissolved in ethanol (25 ml), and an aqueous solution (25 ml) of sodium hydroxide (0.6 g,15 mmol) was added thereto and stirred at 60℃for 1 hour. After the TLC detection reaction is finished, the reaction solution is concentrated, water is added, 1N hydrochloric acid is slowly used for acidification until PH=3-4, and when the solid precipitation is finished, the product is obtained through suction filtration and drying, and the yield is 88%. Step 3 preparation of intermediate 6-bromo-1-sec-butyl-N- ((4, 6-dimethyl-2-oxo-1, 2-dihydropyridin-3-yl) methyl) -1H-indole 4-carboxamide
Under the protection of nitrogen, the intermediate 6-bromo-1H-indole-4-carboxylic acid (1.42 g,5.92 mmol) was added to 25ml DMSO, N-methylmorpholine (3.14 g,31.0 mmol) was slowly added with stirring, EDCI (2.14 g,11.2 mmol), HOAt (1.52 g,11.2 mmol) were added separately, after stirring for 10 min 3- (aminomethyl) -4, 6-dimethylpyridine-2 (1H) -one (1.43 g,7.44 mmol) was added, and the system was stirred overnight to complete the reaction. Pouring the reaction solution into ice water, precipitating a large amount of solids, carrying out suction filtration, and drying a filter cake to obtain white solids, wherein the yield is 69%.
Step 4.1- (sec-butyl) -N- ((4, 6-dimethyl-2-oxo-1, 2-dihydropyridin-3-yl) methyl) -6- (6-methyl-7-oxo-6, 7-dihydro-1H-pyrrolo [2,3-C ] pyridin-4-yl) -1H-indole-4-carboxamide preparation
6-methyl-4- (4, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) -1-p-toluenesulfonyl-1, 6-dihydro-7H-pyrrolo [2,3-C ] pyridin-7-one (513.6 mg,1.2 mmol), 6-bromo-1-sec-butyl-N- ((4, 6-dimethyl-2-oxo-1, 2-dihydropyridin-3 yl) methyl) -1H-indole 4-carboxamide (430 mg,1 mmol), sodium carbonate (381 mg,3.6 mmol) and [1,1' -bis (diphenylphosphine) ferrocene ] palladium dichloride dichloromethane complex (40 mg,0.05 mmol) were added to a round bottom flask followed by dioxane (5 mL) and water (2 mL), nitrogen replaced three times and heated at 110℃for 4 hours under nitrogen. TLC monitored the completion of the reaction, the organic solvent was spun off under reduced pressure, then diluted with water and extracted with ethyl acetate. The ethyl acetate phase was then washed with water and saturated brine, and dried over anhydrous sodium sulfate. Removing the organic solvent under reduced pressure, stirring the solid mixture with silica gel, and purifying on a 200-300 silica gel column to obtain the intermediate product. The intermediate was placed in dioxane (5 mL) and aqueous sodium hydroxide (2 m,5 mL), heated at 90 ℃ for 2 hours, TLC monitored the reaction was complete, and after spinning off the organic solvent under reduced pressure, water was added to dilute and extracted with ethyl acetate. The ethyl acetate phase was washed with water, saturated brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give the product in 23% yield.
1 H NMR(400MHz,DMSO)δ12.13(s,1H),11.57(s,1H),8.22(t,J=5.1Hz,1H),7.80(s,1H),7.62(s,1H),7.59(d,J=3.1Hz,1H),7.43(s,1H),7.37(t,J=2.4Hz,1H),6.86(d,J=3.1Hz,1H),6.48(s,1H),5.89(s,1H),4.65-4.60(m,1H),4.39(d,J=5.0Hz,2H),3.61(s,3H),2.25(s,3H),2.12(s,3H),1.89-1.83(m,2H),1.47(d,J=6.6Hz,3H),0.74(t,J=7.3Hz,3H).
Example 2: preparation of N- ((4, 6-dimethyl-2-oxo-1, 2-dihydropyridin-3-yl) methyl) -6- (6-methyl-7-oxo-6, 7-dihydro-1H-pyrrolo [2,3-C ] pyridin-4-yl) -1- (pentan-2-yl) -1H-indole-4-carboxamide (Compound 2)
The title compound was obtained in 38% yield by the preparation method of example 1 using 2-bromopentane as a starting material.
1 H NMR(400MHz,DMSO)δ12.15(s,1H),11.58(s,1H),8.22(s,1H),7.80(s,1H),7.70–7.52(m,2H),7.40(d,J=18.0Hz,2H),6.87(d,J=2.7Hz,1H),6.49(s,1H),5.88(s,1H),4.65(t,J=28.7Hz,1H),4.40(d,J=4.6Hz,2H),3.62(s,3H),2.25(s,3H),2.12(s,3H),1.98–1.69(m,2H),1.47(d,J=6.5Hz,3H),1.36–0.96(m,2H),0.82(t,J=7.2Hz,3H).
Example 3: preparation of N- ((4, 6-dimethyl-2-oxo-1, 2-dihydropyridin-3-yl) methyl) -6- (6-methyl-7-oxo-6, 7-dihydro-1H-pyrrolo [2,3-C ] pyridin-4-yl) -1- (pentan-3-yl) -1H-indole-4-carboxamide (Compound 3)
The preparation method of example 1 was used to obtain the objective compound in 21% yield using 3-bromopentane as a starting material.
1 H NMR(400MHz,DMSO)δ12.12(s,1H),11.54(s,1H),8.20(t,J=5.3Hz,1H),7.80(s,1H),7.71–7.50(m,1H),7.38(dd,J=9.6,6.9Hz,1H),6.88(d,J=3.1Hz,1H),6.45(s,1H),5.88(s,1H),4.39(d,J=5.0Hz,2H),3.61(s,2H),2.25(s,2H),2.11(s,2H),1.87(dd,J=10.6,5.6Hz,3H),1.23(s,2H),0.69(t,J=7.3Hz,3H).
Example 4: preparation of 1-cyclopentyl-N- ((4, 6-dimethyl-2-oxo-1, 2-dihydropyridin-3-yl) methyl) -6- (6-methyl-7-oxo-6, 7-dihydro-1H-pyrrolo [2,3-C ] pyridin-4-yl) -1H-indole-4-carboxamide (Compound 4)
The title compound was obtained in 25% yield by the preparation method of example 1 using bromocyclopentane as a starting material.
1 H NMR(400MHz,DMSO)δ12.12(s,1H),11.54(s,1H),8.20(t,J=5.0Hz,1H),7.80(s,1H),7.62(s,1H),7.57(d,J=3.2Hz,1H),7.42(s,1H),7.36(t,J=2.6Hz,1H),6.83(d,J=3.2Hz,1H),6.50(s,1H),5.88(s,1H),5.15–4.81(m,1H),4.38(d,J=5.0Hz,2H),3.61(s,3H),2.24(s,3H),2.18(d,J=7.6Hz,2H),2.11(s,3H),1.95–1.61(m,6H).
Example 5: preparation of 1- (cyclohexylmethyl) -N- ((4, 6-dimethyl-2-oxo-1, 2-dihydropyridin-3-yl) methyl) -6- (6-methyl-7-oxo-6, 7-dihydro-1H-pyrrolo [2,3-C ] pyridin-4-yl) -1H-indole-4-carboxamide (Compound 5)
The title compound was obtained in 29% yield by the preparation method of example 1 using bromomethylcyclohexane as a starting material.
1 H NMR(400MHz,DMSO)δ12.12(s,1H),11.54(s,1H),8.20(t,J=5.2Hz,1H),7.74(s,1H),7.60(s,1H),7.45(d,J=3.1Hz,1H),7.39(s,1H),7.37(t,J=2.7Hz,1H),6.81(d,J=3.0Hz,1H),6.50(d,J=22.5Hz,1H),5.88(s,1H),4.38(d,J=5.1Hz,2H),4.09(d,J=7.1Hz,2H),3.61(s,3H),2.24(s,3H),2.11(s,3H),1.78(d,J=22.5Hz,1H),1.62(d,J=19.0Hz,2H),1.50(d,J=12.5Hz,2H),1.23(m,4H),1.17–0.91(m,6H).
Example 6: preparation of 1- (sec-butyl) -N- ((1-methyl-3-oxo-2,3,5,6,6,5,6,6,7,5-hexahydroxyquinolin-4-yl) methyl) -6- (6-methyl-7-oxo-6, 7-dihydro-1H-pyrrolo [2,3-C ] pyridin-4-yl) -1H-indole-4-carboxamide (Compound 6)
Reference example 1 preparation method, wherein step 3 using 4- (aminomethyl) -1-methyl-5, 6,7, 8-four hydrogen isoquinoline-3 (2H) -ketone as raw material, obtained the target compound, yield 27%.
1 H NMR(400MHz,DMSO)δ12.11(s,1H),11.56(s,1H),8.22(t,J=4.0Hz,1H),7.79(s,1H),7.60-7.54(m,2H),7.40(s,1H),7.36(t,J=2.7Hz,1H),6.86(d,J=3.2Hz,1H),6.47(t,J=4.0Hz,1H),4.76–4.65(m,1H),4.41(d,J=5.0Hz,2H),3.61(s,3H),2.80(s,2H),2.11(s,3H),1.92-1.80(m,4H),1.64(s,4H),1.47(d,J=6.7Hz,3H),0.81(t,J=7.3Hz,3H).
Example 7: preparation of N- ((1-methyl-3-oxo-2, 3,5,6,7, 8-hexahydroxyquinolin-4-yl) methyl) -6- (6-methyl-7-oxo-6, 7-dihydro-1H-pyrrolo [2,3-C ] pyridin-4-yl) -1- (pentan-2-yl) -1H-indole-4-carboxamide (Compound 7)
Reference example 1 preparation method, wherein step 1 using 2-bromo pentane as raw material, step 3 using 4- (amino methyl) -1-methyl-5, 6,7, 8-four hydrogen isoquinoline-3 (2H) -ketone as raw material, to obtain the target compound, yield 21%.
1 H NMR(400MHz,DMSO)δ12.12(s,1H),11.56(s,1H),8.22(t,J=4.0Hz,1H),7.79(s,1H),7.60-7.54(m,2H),7.40(s,1H),7.36(t,J=2.7Hz,1H),6.86(d,J=3.2Hz,1H),6.47(t,J=4.0Hz,1H),4.76–4.65(m,1H),4.41(d,J=5.0Hz,2H),3.61(s,3H),2.80(s,2H),2.38(s,2H),2.11(s,3H),1.88-1.78(m,4H),1.64(s,4H),1.47(d,J=6.7Hz,3H),0.82(t,J=7.3Hz,3H).
Example 8: preparation of 1- (cyclohexylmethyl) -N- ((1-methyl-3-oxo-2, 3,5,6,7, 8-hexahydroxyquinolin-4-yl) methyl) -6- (6-methyl-7-oxo-6, 7-dihydro-1H-pyrrolo [2,3-C ] pyridin-4-yl) -1H-indole-4-carboxamide (Compound 8)
Reference example 1 preparation method, wherein step 1 with bromomethyl cyclohexane as raw material, step 3 with 4- (aminomethyl) -1-methyl-5, 6,7, 8-four hydrogen isoquinoline-3 (2H) -ketone as raw material, obtained the target compound, yield 34%.
1 H NMR(400MHz,DMSO)δ12.15(s,1H),11.64(s,1H),8.25(t,J=5.0Hz,1H),7.75(s,1H),7.63(s,1H),7.44(d,J=3.1Hz,1H),7.40(s,1H),7.37(t,J=2.7Hz,1H),6.83(d,J=2.9Hz,1H),6.48(t,J=2.1Hz,1H),4.42(d,J=4.9Hz,2H),4.08(d,J=7.0Hz,2H),3.61(s,3H),2.80(s,2H),2.37(s,2H),2.11(s,3H),1.80(s,1H),1.63(s,6H),1.59(s,1H),1.50(d,J=11.8Hz,2H),1.11-1.08(m,2H),1.06–0.92(m,2H).
Example 9: preparation of 1- (sec-butyl) -N- ((4, 6-dimethyl-2-oxo-1, 2-dihydropyridin-3-yl) methyl) -3-methyl-6- (6-methyl-7-oxo-6, 7-dihydro-1H-pyrrole [2,3-C ] pyridin-4-yl) -1H-indole-4-carboxamide (Compound 9)
Step 1 preparation of intermediate methyl-6-bromo-1-sec-butyl-3-aldehyde-1H-indole-4-carboxylic acid methyl ester
Phosphorus oxychloride (0.83 g,5.43 mmol) was added to anhydrous DMF (50 mL) in a reaction flask under ice bath and stirred for 30 min, methyl-6-bromo-1-sec-butyl-1H-indole-4-carboxylate (1.40 g,4.53 mmol) of the product of example 1 step 1 was dissolved in DMF (50 mL), slowly added to the reaction flask and stirring was continued at room temperature for 2.5H. After the reaction was completed, it was diluted with cold water, pH was adjusted to 8 with 2N sodium hydroxide solution, extracted with ethyl acetate, and the combined organic layer was washed with cold water and brine, dried over anhydrous sodium sulfate, and concentrated in vacuo to give the product in 99% yield.
Step 2 preparation of intermediate 6-bromo-sec-butyl-3-methyl-1H-indole-4-carboxylic acid methyl ester
methyl-6-bromo-1-sec-butyl-3-aldehyde-1H-indole-4-carboxylic acid methyl ester (1.51 g,4.46 mmol) was dissolved in DMF, p-toluenesulfonic acid monohydrate (0.11 g,0.58 mmol), p-toluenesulfonic acid hydrazide (1.08 g,5.8 mmol) were added at room temperature followed by sulfolane 12ml, followed by warming to 100℃for 1 hour. The reaction solution was cooled to room temperature, sodium cyanoborohydride was added in portions, the temperature was raised to 100℃for 2 hours, then cooled to room temperature, and stirring was continued for 16 hours. The reaction solution was diluted with water, extracted with ethyl acetate, and the combined organic phases were washed with cold water, brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and chromatographed to give the product in 34% yield.
Step 3 preparation of intermediate 6-bromo-sec-butyl-3-methyl-1H-indole-4-carboxylic acid
With reference to the procedure of step 2 of example 1, hydrolysis gave the title compound in 90% yield.
Step 4 preparation of intermediate 6-bromo-1-sec-butyl-N- ((4, 6-dimethyl-2-oxo-1, 2-dihydropyridin-3-yl) methyl) 3-methyl-1H-indole 4-carboxamide
Referring to the procedure of step 3 of example 1, the title compound was obtained in 73% yield.
Step 5.1- (sec-butyl) -N- ((4, 6-dimethyl-2-oxo-1, 2-dihydropyridin-3-yl) methyl) -3-methyl-6- (6-methyl-7-oxo-6, 7-dihydro-1H-pyrrolo [2,3-C ] pyridin-4-yl) -1H-indole-4-carboxamide preparation
The procedure of example 1, step 4, was followed to afford the title compound in 24% yield.
1 H NMR(400MHz,DMSO)δ12.10(s,1H),11.45(s,1H),8.18(t,J=4.9Hz,1H),7.64(s,1H),7.36(dd,J=6.5,3.9Hz,2H),7.28(s,1H),7.17(s,1H),6.51(s,1H),5.86(s,1H),4.53(d,J=7.0Hz,1H),4.35(d,J=4.9Hz,2H),3.60(s,3H),2.24(s,3H),2.17(s,3H),2.10(s,3H),1.83(dd,J=11.2,7.3Hz,2H),1.42(d,J=6.7Hz,3H),0.74(t,J=7.3Hz,3H).
Example 10: preparation of 1-cyclohexylmethyl-N- ((4, 6-dimethyl-2-oxo-1, 2-dihydropyridin-3-yl) methyl) -3-methyl-6- (6-methyl-7-oxo-6, 7-dihydro-1H-pyrrolo [2,3-C ] pyridin-4-yl) -1H-indole-4-carboxamide (Compound 10)
The title compound was obtained in 27% yield by the method of example 9 using bromomethylcyclohexane as a starting material.
1 H NMR(400MHz,DMSO)δ12.10(s,1H),11.47(s,1H),8.15(s,1H),7.59(s,1H),7.35(s,2H),7.16(d,J=9.1Hz,2H),6.51(s,2H),4.38(d,J=4.7Hz,2H),3.99(d,J=7.0Hz,2H),3.75–3.48(m,3H),2.35(d,J=15.6Hz,3H),2.17(s,3H),2.09(s,3H),1.75(s,1H),1.63(s,2H),1.51(d,J=13.1Hz,2H),1.23(m,4H),1.18–1.06(m,3H),0.98(d,J=11.6Hz,6H).
Example 11: preparation of 1- (sec-butyl) -3-methyl-N- ((1-methyl-3-oxo-2,3,5,6,7,5,6,7,8-hexahydroxyquinolin-4-yl) methyl) -6- (6-methyl-7-oxo-6, 7-dihydro-1H-pyrrolo [2,3-C ] pyridin-4-yl) -1H-indole-4-carboxamide (Compound 11)
The procedure of example 9 is followed, wherein step 4 is performed using 4- (aminomethyl) -1-methyl-5, 6,7, 8-tetrahydroisoquinolin-3 (2H) -one as a starting material, to obtain the objective compound in 20% yield.
1 H NMR(400MHz,DMSO)δ12.10(s,1H),11.48(s,1H),8.15(t,J=4.9Hz,1H),7.65(s,1H),7.35(dd,J=8.0,5.3Hz,2H),7.28(s,1H),7.18(s,1H),6.52(s,1H),4.53(d,J=7.2Hz,1H),4.39(d,J=4.8Hz,2H),3.60(s,3H),2.78(s,2H),2.37(s,2H),2.19(s,3H),2.09(s,3H),1.92–1.74(m,2H),1.63(s,4H),1.42(d,J=6.6Hz,3H),0.74(t,J=7.3Hz,3H).
Example 12: preparation of 1- (cyclohexylmethyl) -3-methyl-N- ((1-methyl-3-oxo-2,3,5,6,6,6,7,8-hexahydroxyquinolin-4-yl) methyl) -6- (6-methyl-7-oxo-6, 7-dihydro-1H-pyrrolo [2,3-C ] pyridin-4-yl) -1H-indole-4-carboxamide (Compound 12)
The procedure of example 9 was followed, wherein step 1 was conducted using bromomethylcyclohexane as a starting material and step 4 was conducted using 4- (aminomethyl) -1-methyl-5, 6,7, 8-tetrahydroisoquinolin-3 (2H) -one as a starting material, to give the objective compound in 23% yield.
1 H NMR(400MHz,DMSO)δ12.10(s,1H),11.45(s,1H),8.18(t,J=4.9Hz,1H),7.59(s,1H),7.43–7.24(m,1H),7.15(d,J=8.0Hz,2H),6.47(d,J=34.1Hz,1H),5.81(d,J=40.1Hz,1H),4.35(d,J=4.8Hz,2H),3.99(d,J=6.9Hz,2H),3.60(s,3H),2.23(s,3H),2.17(d,J=14.8Hz,3H),2.10(s,4H),1.21(d,J=17.0Hz,4H),1.14(m,8H),0.98(m,3H).
Example 13: preparation of 1-cyclopentyl-N- ((4, 6-dimethyl-2-oxo-1, 2-dihydropyridin-3-yl) methyl) -6- (6-methyl-7-oxo-6, 7-dihydro-1H-pyrrolo [2,3-C ] pyridin-4-yl) -1H-indazole-4-carboxamide (Compound 13)
Starting with cyclopentane bromide and 6-bromo-1H-indazole-4-carboxylic acid, the title compound was obtained in 26% yield by the method of example 1.
1 H NMR(400MHz,DMSO)δ12.23(s,1H),11.60(s,1H),8.56(s,1H),8.34(s,1H),7.96(s,1H),7.77(s,1H),7.54(s,1H),7.39(s,1H),6.54(s,1H),5.88(s,1H),5.26(s,1H),4.40(s,2H),3.62(s,3H),2.23(s,3H),2.12(s,3H),2.02-1.96(m,4H),1.92-1.88(m,2H),1.67-1.62(m,2H).
Example 14: preparation of 1-cyclopentyl-N- ((1-methyl-3-oxo-2, 3,5,6,7, 8-hexahydroxyquinolin-4-yl) methyl) -6- (6-methyl-7-oxo-6, 7-dihydro-1H-pyrrolo [2,3-C ] pyridin-4-yl) -1H-indazole-4-carboxamide (Compound 14)
The method of example 1 was referred to, wherein step 1 was conducted using bromocyclopentane and 6-bromo-1H-indazole-4-carboxylic acid as starting materials, and step 3 was conducted using 4- (aminomethyl) -1-methyl-5, 6,7, 8-tetrahydroisoquinolin-3 (2H) -one as starting material, to obtain the objective compound in 32% yield.
1 H NMR(400MHz,DMSO)δ12.22(s,1H),11.59(s,1H),8.54(s,1H),8.34(s,1H),7.95(s,1H),7.75(s,1H),7.53(s,1H),7.38(s,1H),6.53(s,1H),5.26(t,J=8.0Hz,1H),4.42(d,J=4.4Hz,2H),3.61(s,3H),2.76(s,2H),2.37(s,2H),2.11-1.98(m,4H),2.07–1.94(m,2H),1.88(s,2H),1.70-1.64(m,2H),1.63(s,5H).
The beneficial effects of the compounds of the invention are demonstrated below by experimental examples.
Experimental example 1: in vitro enzyme inhibition assay
1. Experimental method
His-tagged EZH2 or BRD4 is cloned, expressed and purified to homogeneity. EZH2 or BRD4 binding and inhibition was assessed by detecting biotinylated H4-tetraacetyl peptide (AnaSpec, H4k5/8/12/16 (Ac), biotin-labeled) interactions with the target using the AlaphaScreen technique. BRD4 (2 nM final) is combined with peptide (15 nM final) in 50mM HEPES (pH 7.3), 10mM NaCl, 0.25mM TCEP, 0.1% (w/v) BSA and 0.005% (w/v) Brij-35 in 384-well ProxiPlate in the presence of a dilution series of compound in DMSO. After incubation for 20 minutes at room temperature at 25 degrees celsius, the alpha streptavidin donor and acceptor beads were added to a final concentration of 5 μg/mL. After 2 hours of equilibration, plates were read on an Envison instrument and IC was calculated using fitting 50 。
JQ1 (a known BET bromodomain inhibitor) was used as a positive control with GSK126 (a known selective EZH2 inhibitor).
2. Experimental results
Table 1 inhibitory Activity of Compounds against enzymes.
It can be seen that the compounds of the present invention are effective in inhibiting the activity of EZH2 or BRD4, and in particular that compounds 1-3, 5 are effective in inhibiting both EZH2 and BRD 4.
Experimental example 2: in vitro tumor cell inhibition assay
1. Experimental method
Pancreatic cancer cell lines AsPC-1 (human metastatic pancreatic cancer cells) and BxPC-3 (human in situ pancreatic cancer cells) were purchased from american standard collection for organisms (American Type Culture Collection, ATCC), RPMI1640 medium, and Fetal Bovine Serum (FBS) were purchased from the company GIBICO in the united states; penicillin and streptomycin were purchased from Dalianbao biosome; cultured cells were purchased from Corning company using plates, 96-well plates, etc.; centrifuge tubes of various sizes were purchased from BD company; MTT reagent was purchased from the Japan same-kernel chemical institute (Donjindo).
Cell culture conditions were all cultured with conventional high-glucose RPMI1640 complete medium containing 10% Fetal Bovine Serum (FBS), 100IU/mL penicillin, 100. Mu.g/mL streptomycin at 37℃with 5% CO 2 Is cultured in an incubator of (a).
In order to examine the proliferation effect of the novel compounds on cells. Cells in the logarithmic growth phase were collected, single cell suspensions were adjusted to a cell concentration of 1000 to 2000 cells/mL, and inoculated into 96-well plates at 100uL per well. Stock solutions of the compounds (10 mM/L in DMSO) were diluted to different concentrations with medium using a triple dilution method. Adding into 96-well plate at a volume of 100uL per well, with the highest concentration of 30uM and the lowest concentration of 0.1uM, setting 3 multiple wells per drug concentration, treating cells with culture medium containing 0.1% DMSO and pure culture medium as negative control, placing into cell incubator, culturing for 6 days, detecting mitochondrial dehydrogenase activity of cells with MTT, and calculating half-effective Inhibitory Concentration (IC) of new compound on tumor cells 50 μM) values (Table 1).
2. Experimental results
TABLE 2 proliferation inhibiting Activity of Compounds against tumor cell lines
Examples | AsPC-1IC 50 (μM) | BxPC-3(μM) |
1 | 1.6 | 3.2 |
2 | 1.2 | 3.3 |
3 | 1.7 | 3.8 |
4 | 4.4 | 7.9 |
5 | 3.4 | 7.3 |
6 | 3.2 | 8.7 |
7 | 4.0 | 12.3 |
8 | 15.1 | 13.6 |
9 | 4.3 | 9.1 |
10 | 8.4 | 8.7 |
11 | 9.2 | 13.8 |
12 | >20 | >20 |
13 | 20.1 | 17.2 |
14 | 15.2 | 18.1 |
GSK126 | 10.2 | 13.7 |
JQ1 | 3.7 | 1.4 |
It can be seen that the compounds of the present invention are effective in inhibiting the activity of AsPC-1 (human metastatic pancreatic cancer cells) and BxPC-3 (human in situ pancreatic cancer cells).
In summary, a class of benzoheterocycle-pyridone derivatives, and a preparation method and application thereof are provided. Experimental results show that the compound can effectively inhibit the activity of EZH2 or BRD4, and particularly the compounds 1-3 and 5 can simultaneously effectively inhibit the activity of EZH2 and BRD 4. Thus, the compounds of the present invention may be used in the preparation of EZH2 and/or BRD4 inhibitors, and in the prevention and/or treatment of diseases associated with EZH2 and/or BRD4 activity, including but not limited to follicular lymphoma, diffuse large B-cell lymphoma, breast cancer, lung cancer, colorectal cancer, prostate cancer, gastric cancer, inflammation, pancreatic cancer, cardiovascular disease, central nervous system disease, immunodeficiency virus infection. Proliferation inhibition activity experiments on tumor cell lines further prove that the compound can effectively inhibit the activity of AsPC-1 (human metastatic pancreatic cancer cells) and BxPC-3 (human in-situ pancreatic cancer cells). Thus, the compounds of the present invention can be used for the preparation of a medicament for the prevention and/or treatment of pancreatic cancer (including metastatic pancreatic cancer or pancreatic cancer in situ).
Claims (9)
1. A compound or a pharmaceutically acceptable salt thereof, characterized in that: the structure of the compound is shown in a formula III:
wherein X is selected from C 1-5 Alkyl, LZ; l is selected from 1-2 methylene groups, and Z is selected from 5-6 membered saturated cycloalkyl.
2. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein: the compound is selected from:
3. a process for preparing a compound according to any one of claims 1-2, characterized in that: the method comprises the following steps:
(1) Carrying out hydrolysis reaction on the compound I-1 to obtain a compound I-2;
(2) Reacting the compound I-2 with a compound I-3 to obtain I-4;
(3) Reacting the compound I-4 with a compound I-5, and then deprotecting to obtain a compound shown in a formula III;
wherein X is as defined in any one of claims 1-2; t is halogen; r is R 5 Is an amino protecting group.
4. A method according to claim 3, characterized in that: the T is bromine; r is R 5 Is p-toluenesulfonyl.
5. A medicament for preventing and/or treating diseases associated with EZH2 and BRD4 activity, characterized in that: a preparation prepared by adding pharmaceutically acceptable auxiliary materials into the compound or pharmaceutically acceptable salt thereof as active ingredient in any one of claims 1-2.
6. Use of a compound according to any one of claims 1-2, or a pharmaceutically acceptable salt thereof, for the preparation of an EZH2 and BRD4 inhibitor.
7. Use according to claim 6, characterized in that: the EZH2 and BRD4 inhibitor is a medicament for preventing and/or treating diseases related to EZH2 and BRD4 activities.
8. Use according to claim 7, characterized in that: the diseases related to EZH2 and BRD4 activity are follicular lymphoma, diffuse large B cell lymphoma, breast cancer, lung cancer, colorectal cancer, prostatic cancer, gastric cancer, inflammation, pancreatic cancer, cardiovascular disease, central nervous system disease and immunodeficiency virus infection.
9. Use according to claim 8, characterized in that: the pancreatic cancer is metastatic pancreatic cancer or in situ pancreatic cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210609107.0A CN114805350B (en) | 2022-05-31 | 2022-05-31 | Benzo heterocycle-pyridone derivative, and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210609107.0A CN114805350B (en) | 2022-05-31 | 2022-05-31 | Benzo heterocycle-pyridone derivative, and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114805350A CN114805350A (en) | 2022-07-29 |
CN114805350B true CN114805350B (en) | 2023-10-20 |
Family
ID=82518444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210609107.0A Active CN114805350B (en) | 2022-05-31 | 2022-05-31 | Benzo heterocycle-pyridone derivative, and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114805350B (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105037360A (en) * | 2014-04-28 | 2015-11-11 | 四川大学 | Pyridone derivative, preparation method and application thereof |
CN107573336A (en) * | 2016-07-05 | 2018-01-12 | 四川大学 | Benzheterocycle carboxamide pyridine ketone derivatives and its production and use |
CN110776508A (en) * | 2018-07-27 | 2020-02-11 | 成都海创药业有限公司 | BRD4 inhibitor and preparation method and application thereof |
CN113402515A (en) * | 2021-05-12 | 2021-09-17 | 四川大学华西医院 | Indole compound and preparation method and application thereof |
CN113527275A (en) * | 2021-07-20 | 2021-10-22 | 成都师范学院 | SKLB1039 compound and preparation method and application thereof |
-
2022
- 2022-05-31 CN CN202210609107.0A patent/CN114805350B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105037360A (en) * | 2014-04-28 | 2015-11-11 | 四川大学 | Pyridone derivative, preparation method and application thereof |
CN107573336A (en) * | 2016-07-05 | 2018-01-12 | 四川大学 | Benzheterocycle carboxamide pyridine ketone derivatives and its production and use |
CN110776508A (en) * | 2018-07-27 | 2020-02-11 | 成都海创药业有限公司 | BRD4 inhibitor and preparation method and application thereof |
CN113402515A (en) * | 2021-05-12 | 2021-09-17 | 四川大学华西医院 | Indole compound and preparation method and application thereof |
CN113527275A (en) * | 2021-07-20 | 2021-10-22 | 成都师范学院 | SKLB1039 compound and preparation method and application thereof |
Non-Patent Citations (10)
Title |
---|
Niannian Huang,等.Design, Synthesis, and Biological Evaluation of a Potent Dual EZH2-BRD4 Inhibitor for the Treatment of Some Solid Tumors.Journal of Medicinal Chemistry.2023,第66卷(第04期),第2646-2662页. * |
何冰 ; 等.EZH2抑制剂中间体5-溴-1-环己基-1H-吲唑-3-羧酸的合成.成都师范学院学报.2019,第35卷(第11期),第103-107页. * |
吴芳 ; 等.BRD4抑制剂抗肿瘤机制研究进展.肿瘤药学.2019,第09卷(第02期),第177-183页. * |
奉强 ; 等.1/2,5-二取代吲唑-3-甲酰胺衍生物的合成及其抗肿瘤活性.合成化学.2017,第25卷(第09期),第721-729+768页. * |
张华鹏.靶向抑制BRD4的抗肝癌作用及其分子机制的研究.中国博士学位论文全文数据库医药卫生科技辑.2019,(第07期),第E072-58页. * |
张晓攀 ; 等.EZH2甲基转移酶抑制剂的设计、合成及其抑制活性.精细化工.2020,第37卷(第10期),第2083-2089页. * |
曹冉 ; 等.BET溴结构域抑制剂的研究进展.中国药物化学杂志.2020,第30卷(第06期),第347-358页. * |
李欣 ; 等.EZH2相关研究进展.临床合理用药杂志.2017,第10卷(第19期),第169-171页. * |
王泽瑜 ; 等.溴结构域蛋白4及其抑制剂的研究进展.中国药学杂志.2017,第52卷(第15期),第1293-1300页. * |
秦宇 ; 等.EZH2抑制剂与肿瘤治疗.生命的化学.2017,第37卷(第03期),第401-407页. * |
Also Published As
Publication number | Publication date |
---|---|
CN114805350A (en) | 2022-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3070089B1 (en) | Aminomethyl tryptanthrin derivative, preparation method and application thereof | |
TWI438193B (en) | Acylthiourea compound or salt thereof, and use thereof | |
JPWO2002088112A1 (en) | Heterocyclic compound and antitumor agent containing the same as active ingredient | |
CN112300153B (en) | Heterocyclic compound, pharmaceutical composition and application | |
WO2016192132A1 (en) | Pyrimidine derivative serving as alk inhibitor | |
JP2019526605A (en) | Crystal form and salt form of substituted 2-H-pyrazole derivative and method for producing the same | |
CN116283953A (en) | Indoline compound containing thiazole structure, and preparation method and application thereof | |
JP2004524349A (en) | Chemical derivatives and their use as anti-telomerase agents | |
CN115304603A (en) | Preparation and application of quinazoline inhibitor | |
EP0966462B1 (en) | Heterocyclic compounds useful as oxido-squalene cyclase inhibitors | |
WO2023174400A1 (en) | Salt of substituted amino six-membered nitric heterocyclic compound, crystal form thereof, method for preparing same, and use thereof | |
CN114805350B (en) | Benzo heterocycle-pyridone derivative, and preparation method and application thereof | |
EP1424326B1 (en) | Fused-polycyclic compounds | |
US20060111368A1 (en) | Phosphodiesterase inhibitor | |
CN115490689B (en) | Irreversible KRAS G12C Preparation and application of inhibitor | |
CN113402515B (en) | Indole compound and preparation method and application thereof | |
CN102584679B (en) | Benzocarbazole acylamide compound and preparation method and application thereof | |
SK11372001A3 (en) | Piperidine and piperazine derivatives as inhibitors of the a'beta' fibril formation | |
CN111108083A (en) | Use of aminomethylene cyclohexane 1, 3-dione compounds | |
CN113493414B (en) | Deuterated substituted butenamide and preparation method and application thereof | |
WO2004108723A1 (en) | 4,5-dihydro-imidazo[4,5,1-ii]quinolin-6-ones as parp inhibitors | |
CN118702679A (en) | Compound with EZH2/BRD4 double-target activity, pharmaceutical composition, and preparation method and application thereof | |
JP2009073743A (en) | New condensed cyclic pyrimidine compound or its salt, and its medicine composition | |
AU2006228142A1 (en) | Imidazopyridine derivatives useful as iNOS inhibitors | |
RU2610275C2 (en) | Glutarimide derivative, use thereof, pharmaceutical composition based thereon, synthesis method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |